Navigation Links
Stemedica's President Delivers Keynote Address at Swiss-Russian Forum
Date:9/17/2009

SAN DIEGO, Sept. 17 /PRNewswire/ -- Dr. Nikolai Tankovich, President of Stemedica, delivered the keynote speech at the Crossing Visions Summit held in Moscow from September 14th - 16th. His presentation at a forum of top Russian and Swiss political, economic and business leaders featured advances in stem cell technology. The Swiss delegation invited Dr. Tankovich, not only for his scientific expertise, but as an example of an on-going scientific collaboration that Stemedica has established between Switzerland and Russia.

"We are delighted that Dr. Tankovich has accepted our invitation to be the keynote speaker at our collaborative forum in Moscow. His expertise in stem cells places him among the premier researchers and clinicians in regenerative medicine," stated Eric Maire, Senior Director Economic Development, State of Vaud, Switzerland.

At the forum, a delegation of over 100 leaders from Switzerland's government, business and biotech sectors met with over 300 of Russia's executives and policy makers. The purpose of the forum was to further commercial relationships between the two countries. During the forum, a number of collaborative agreements between the two countries were signed paving the way for new forms of long-term, forward-looking cooperative relationships.

"We are especially pleased with the outcome of this forum and believe it has been an example of the intensification of the ties that have, and continue to, bind Russia to Switzerland," said Walter B. Gyger, Ambassador of Switzerland to the Russian Federation. The Ambassador further stated, "We are very pleased that Stemedica, a prime example of collaboration between Switzerland and Russia, has chosen Switzerland for its International Headquarters. Its advancement and leadership in the stem cell industry is very impressive and we look forward to supporting them in their research, development and manufacturing efforts."

"I am truly honored to have been selected by the Swiss Government to present Stemedica's cutting edge stem cell technologies to this conference on innovation and science," said Dr. Tankovich. "The research and development collaboration between Russia and Switzerland fits Stemedica's tactical and strategic initiatives as we already have on-going business and research operations in these two great countries as well as in important marketplace leaders like the United States and Korea. We're delighted with the enthusiasm and long-term commitments being made at this Forum as well as the media interest that this event has generated here in Russia. Such interest and support bodes well for the entire stem cell industry."

Maynard A. Howe, PhD, Stemedica's Vice Chairman and CEO was also in attendance at the Summit. Dr. Howe emphasized the importance of these strategic relationships. "Stemedica is committed to working with the world's best and brightest as we work to build a better future for the stem cell industry as well as those who will benefit from our collective efforts. This type of alliance fosters the kind of technology sharing in the biotech and pharmaceutical industries that will soon be changing the lives of millions suffering from debilitating diseases and conditions."

Dr. Tankovich and other Stemedica colleagues will continue to present at national and international conferences like the Crossing Visions Summit as Stemedica further establishes itself as a leader in the stem cell and biopharmaceutical industries.

About Stemedica Cell Technologies, Inc.

Stemedica Cell Technologies Inc. (www.stemedica.com) is a specialty biopharmaceutical company that is committed to the development and manufacturing of best-in-class adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and human clinical trials. The company is currently developing regulatory pathways for stroke and wound repair. Stemedica is headquartered in San Diego, California.

For more information regarding this Media Release or Stemedica Cell Technologies, contact Dave McGuigan at dmcguigan@stemedica.com.


'/>"/>
SOURCE Stemedica Cell Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Family Research Council: Senator Baucus Undermines President Obamas Abortion Funding Claim
2. AFSCME President McEntee: "Finance Committee Health Care Bill is Deeply Flawed"
3. Cynosure Names Paul Cardarelli Vice President of Business Development
4. Marc Russo Named Vice President of Senior Markets at Blue Shield of California
5. Marc Russo Named Vice President of Individual, Small Group, and Government Business Unit at Blue Shield of California
6. Care Improvement Plus Names Anthony Colistra as Vice President, Market Growth and Development
7. Schofield Media Names Brian Reshefsky Group President
8. Statement from Stuart L. Weinstein, MD, Chairman, Doctors for Medical Liability Reform on President Obamas Health Care Address to Congress
9. Broad Health Coalition Applauds President Obamas Commitment to Medical Liability Reform
10. The Presidents Speech & Mental Health Care
11. President Obama Misleads Public on Health Care for Illegal Aliens; Illegal Aliens Would Benefit Under H.R. 3200
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... 2016 , ... Comfort Keepers® of San Diego, CA is excited to announce ... program to drive cancer patients to and from their cancer treatments. Comfort Keepers ... of life and ongoing independence. Getting to and from medical treatments is one ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine ... Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital ... area economy by obtaining investment capital for emerging technology companies. SCP has ... have already resulted in more than a million dollars of capital investment for ...
(Date:6/24/2016)... MD (PRWEB) , ... June 24, 2016 , ... ... protocols for human induced pluripotent stem (iPS) cells and other difficult to transfect ... G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is a ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 /PRNewswire/ ... Diabetes Tomorrow,s Leaders Scholarship is any indication, the future ... today online at www.diabetesscholars.org by the Diabetes ... stand in the way of academic and community service ... scholarship program since 2012, and continues to advocate for ...
Breaking Medicine Technology: